The field of drug and gene delivery involves the development and delivery of drugs, genes, and/or gene products that ultimately alter protein expression and function of the cells, tissues, and living organisms. Drug delivery devices are the tools used to deliver the drug through the specific route of administration. While, gene delivery is the process of introducing foreign genetic material, such as DNA or RNA, into host cells.
Rise in burden of chronic diseases, such as infectious disease, cardiovascular disease, cancer, and diabetes, increasing demand for drug or gene delivery devices, increasing funding for cell and gene therapies, and rise in approvals for gene therapies are major factors expected to augment the growth of the global drug and gene delivery devicesmarket over the forecast period.
For instance, in November 2022, Imunon, Inc. and Acuitas Therapeutics signed an agreement to evaluate the combination of IMUNON’s PLACCINE nucleic acid vaccine constructs formulated with Acuitas’ proprietary lipid delivery technology. Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.
- This report provides in-depth analysis of the global drug and gene delivery devicesmarket, and provides market size (US$ Thousand) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global drug and gene delivery devicesmarket based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Dickinson and Company, Helixmith Co., Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global drug and gene delivery devicesmarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug and gene delivery devicesmarket.
-
- Sub-retinal Injection Cannula
- Extension Tube
- Intravenous Catheter
- Sterile Insulin Syringe
- Pre-filled Syringe
- Infusion Bags
-
- Luxturna (Drug Delivery Devices)
- Yescarta (Drug Delivery Devices)
- Zolgensma (Drug Delivery Devices)
- Kymriah (Drug Delivery Devices)
- Provenge (Drug Delivery Devices)
- Strimvelis (Drug Delivery Devices)
-
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
-
- Pfizer, Inc.
- Novartis AG
- Kite Pharma, Inc.
- Bluebird bio, Inc.
- Vericel Corporation
- uniQure N.V.
- Spark Therapeutics, Inc.
- Renova Therapeutics
- Orchard Therapeutics plc
- Kolon Tissue Gene, Inc.
- Human Stem Cell Institute
- Amgen, Inc.
- Dendreon Pharmaceuticals
- Helixmith Co.
- Bausch & Lomb Incorporated, Ltd (ViroMed Co., Ltd)
- Becton Dickinson and Company
- Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
